TER Teradyne

Q1 2025 10-Q

Filed: May 2, 2025Period ending Mar 30, 2025

Health Care

Instruments For Meas & Testing of Electricity & Elec SignalsSEC EDGAR

Teradyne (TER) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 2, 2025 for the fiscal period ending Mar 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New restructuring risk due to Robotics go-to-market consolidation triggering $9.2M severance for ~150 employees
• Most updated financial risk: Cash decreased by $102.3M to $621.5M, driven by $157.5M stock repurchases and $61.8M investing outflows

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$686M

▲ +14.3% YoY

Net Income

$99M

▲ +54.1% YoY

Net Margin

14.4%

▲ +372bp YoY

Source: XBRL data from Teradyne Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Teradyne Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Teradyne

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.